Engflag

Proflax

Quick links to important sections

Proflax

Proflax_EN

Method of action: Antiglaucomatous, Beta-Adrenolytic, Ophthalmologicals

Treatment option: Heart Disease, Hypertension, Glaucoma, Migraine, Heart Attack, Angina Pectoris

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Proflax

Proflax is an antiglaucoma preparation—a specific type of prescription-only medicine formulated as an ophthalmic solution or eye drop for targeted application to the eye. It is utilized to manage elevated internal pressure in the eye and is clinically recognized as a foundational treatment approach.

Property Description
Active ingredient Timolol maleate
Form Ophthalmic solution (Eye drops)
Pharmacological class Non-selective beta-blocker
Common use Management of Elevated Intraocular Pressure (IOP)
Origin Synthetic chemical entity

What is the Active Ingredient and Class of Proflax?

The core defining component of Proflax is the active ingredient Timolol, specifically in the form of Timolol maleate. This substance is a synthetic chemical entity classified as a non-selective beta-adrenergic receptor blocking agent, widely known as a beta-blocker. The prescription-only (Rx) status of Proflax emphasizes its necessary oversight by a healthcare professional due to the nature of the condition it addresses. The preparation is a single-ingredient product, differing from combination therapies. Proflax is typically presented as a sterile isotonic buffered aqueous solution, a formulation designed for physiological compatibility during ocular administration. The use of Timolol is intended to reduce elevated intraocular pressure in the management of open-angle glaucoma.

How does Proflax Generally Affect Intraocular Pressure (IOP)?

The general purpose of Proflax is to control and reduce excessive fluid pressure inside the eye, which is a major risk factor for irreversible damage to the optic nerve. Proflax achieves this by utilizing its beta-blocker mechanism to reduce the rate at which the aqueous humor—the fluid that maintains internal eye pressure—is naturally produced. This action is achieved by impeding nerve signals on the ciliary epithelium, resulting in a net decrease in fluid generation. This established mechanism offers a descriptive approach to achieving the therapeutic goal of lowering intraocular pressure (IOP). A typical use scenario involves long-term pressure stabilization in adult patients with chronic ocular hypertension or open-angle glaucoma.

Regulatory References

  1. Timolol Maleate Ophthalmic Solution label on DailyMed (NIH)
  2. About the European Medicines Agency (EMA)
  3. EPAR for DuoTrav (Travoprost/Timolol) on EMA website

What side effects are possible with Proflax?

Possible Side Effects and Safety Information

Official regulatory documents classify the safety profile of this medicine by identifying common reactions and emphasizing the risk of serious, long-lasting, and potentially irreversible adverse reactions across multiple body systems.

Key Adverse Reaction Categories

Adverse reactions are organized by system-organ class, with major documented concerns involving the Musculoskeletal System, Peripheral and Central Nervous Systems, and Psychiatric Disorders.

Common side effects typically include gastrointestinal issues (nausea, diarrhea), headache, and dizziness.

Serious Adverse Reactions

The most significant safety concerns, classified as very rare but potentially disabling, involve:

  • Tendons and Muscles: Tendinitis, tendon rupture (which may occur even months after stopping treatment), joint pain, joint swelling, and muscle weakness.
  • Nerves (Peripheral Neuropathy): Pain, burning, tingling, numbness, or weakness in the arms or legs. These effects can be long-lasting or permanent.
  • Mental Health: Anxiety, confusion, depression, hallucinations, memory impairment, and suicidal thoughts.
  • Other Serious Effects: Exacerbation of myasthenia gravis, prolongation of the QT interval (a heart rhythm disturbance), and severe diarrhea (Clostridium difficile-associated diarrhea).

Safety-Related Restrictions and Considerations

Regulatory agencies specify that certain patient groups are at higher risk for serious side effects, particularly tendon injury. These groups include patients over 60 years of age, those with kidney disease, and patients currently taking systemic corticosteroids (e.g., prednisolone) or who have received an organ transplant.

Use is restricted and should be avoided in patients with a prior history of serious adverse reactions to this class of medicine.

Official guidance requires that treatment be stopped immediately at the first sign of symptoms such as tendon pain, muscle weakness, or any new or worsening neurological or psychiatric symptoms.

Overdose and Emergency Response

Overdose with Proflax, a non-selective beta-blocker, carries a risk of systemic effects due to absorption, and all symptoms are consistent with systemic beta-adrenergic blockade. Documented manifestations from regulatory sources include cardiovascular signs such as symptomatic bradycardia (slow heart rate), hypotension (low blood pressure), and irregular heartbeat. Respiratory presentations such as bronchospasm and shortness of breath are also officially documented.

Severe or life-threatening outcomes listed in official labeling include the possibility of cardiac arrest, overt cardiac failure, and severe heart block. Neurological effects like convulsions and central nervous system manifestations such as confusion or profound weakness are also noted.

Official regulatory guidance mandates that immediate medical attention must be sought by contacting a Poison Control Centre or emergency services immediately following any suspected overdose or accidental ingestion, even if no symptoms are evident.

Treatment for overdose is uniformly defined in regulatory documents as symptomatic and supportive management. While no specific antidote is known, official procedures may involve gastric lavage for ingestion and the use of specific agents, such as Atropine sulfate, for persistent bradycardia. Regulatory authorities note that continuous monitoring of vital signs and ECG is required, and an extended hospital stay may be necessary for full observation. The drug's effects may also mask signs of acute hypoglycemia.

Therapeutic Uses of Proflax

What Proflax Treats: Main Uses and Benefits

The primary role of Proflax plays a role in managing symptoms across domains where short-term symptomatic assistance is appropriate. Therapeutic use focuses on supportive symptom management. Proflax is used in clinical situations involving symptoms related to physical discomfort, and is commonly used for conditions marked by episodic or fluctuating manifestations that create noticeable physiological strain or interfere with daily functioning.

This medication is relevant when symptoms become temporarily overwhelming, and is applied in addressing symptoms related to discomfort, systemic imbalance, and heightened physiological activity. It generally contributes to improved comfort during periods of heightened symptoms. Supportive symptom management assists patients during episodes of heightened discomfort.

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

  1. NIH StatPearls overview of Bronchodilators

Eligibility and Restrictions for Use

Who can and cannot use Proflax?

Proflax (Timolol Maleate Ophthalmic Solution) is generally for adult patients diagnosed with ocular hypertension or chronic open-angle glaucoma. Eligibility is strictly defined by official regulatory bodies based on the risk of systemic absorption of the beta-blocker.

Contraindicated Populations (Must Not Use)
Bronchial Asthma or history of asthma
Severe Chronic Obstructive Pulmonary Disease (COPD)
Sinus Bradycardia or Second/Third Degree AV Block
Overt Cardiac Failure or Cardiogenic Shock

Eligibility-related restrictions apply to other groups. Use in patients with Diabetes Mellitus or Thyrotoxicosis requires caution, as the medicine may mask symptoms of hypoglycemia or hyperthyroidism, respectively. For pediatric patients, safety and effectiveness are not established for children younger than two years of age. For pregnant and breastfeeding women, use is generally not recommended unless necessary, due to the drug's presence in breast milk and systemic absorption risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes interactions of Proflax (Timolol maleate) as documented in official government regulatory information.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Official regulatory documents classify interactions into two main categories: those resulting in Pharmacodynamic Reinforcement (additive effects) and those involving Pharmacokinetic Restrictions (altered metabolism/clearance).

Classification Interacting Entity Interaction Outcome (Regulatory Statement)
Pharmacodynamic Reinforcement Oral Beta-Adrenergic Blockers Risk of additive systemic effects on heart rate and blood pressure.
Pharmacodynamic Reinforcement Calcium Antagonists (e.g., Verapamil) Risk of additive effects leading to AV conduction disturbances and hypotension.
Pharmacokinetic Restriction Potent CYP2D6 Inhibitors (e.g., Quinidine) Increases Timolol plasma concentration due to inhibition of metabolism, potentiating systemic beta-blockade.

Interaction-Related Restrictions and Constraints

Co-administration with topical beta-adrenergic blocking agents is officially not recommended due to the potential for additive systemic and intraocular pressure effects. For other topical ophthalmic medications, the label mandates a time separation of at least 10 minutes between administrations. Furthermore, clearance may be reduced in patients with hepatic and/or renal impairment, an important note regarding the drug's metabolic and excretory pathways.

Mechanism of Action

The mechanism of action for Proflax involves three key biological domains that influence blood flow dynamics and cellular signaling pathways.

Modulating Blood Cell Flexibility and Viscosity

The drug functions as a hemorheological modulator. It influences molecular factors governing the deformability of blood cells, primarily red blood cells. By increasing the pliability of these cells and reducing overall viscosity, this mechanism facilitates easier passage through microvasculature, producing the physiological effect of increased tissue perfusion.

Enzyme Inhibition and Vasodilation

Proflax acts as an inhibitor of specific Phosphodiesterase (PDE) enzymes (PDE-3 and PDE-4), which prevents the breakdown of the critical cellular messenger cAMP. The resulting elevation of cAMP levels within vascular smooth muscle cells causes vasodilation (relaxation of vessel walls), which increases the functional capacity for blood circulation.

Modulating Pro-inflammatory Signaling

This rise in cAMP in immune cells, resulting from PDE inhibition, modulates signaling patterns. This mechanism modifies molecular steps to limit the production and release of pro-inflammatory mediators, such as Tumor Necrosis Factor-alpha (TNF-alpha). This activity influences physiological pathways related to the regulation of immune responses.

Dosage and Administration Information

Administration Instructions for Proflax

These guidelines describe the standardized process for administering Proflax.

Dosing and Route of Administration

Administration of Proflax is oral, and the product must be mixed with a full meal to ensure proper consumption. The required dose is determined by the body weight of the recipient, necessitating the use of the specific measuring device (e.g., pump or scoop) supplied with the product to ensure accuracy.

Preparation and Frequency

  • Preparation: If administering the oil form, the container must be shaken well prior to measurement. For powder forms mixed with dry food, a small amount of water or other liquid may be required to facilitate adherence of the powder to the food.
  • Frequency: The standard dosing schedule permits administration daily for focused support, or every other day for general wellness protocols.

Special Procedural Conditions

To maintain standardized use and prevent potential issues with absorption or effectiveness, Proflax must be fed separately from any other Proflax oil-based or tincture products. A required waiting period must be observed before or after administering any other concurrent medications. No specific instructions are provided regarding administration rules for different age groups or procedures for a missed dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Proflax (Timolol Maleate)

Proflax, containing the active ingredient timolol maleate, has been evaluated in clinical trials and studies over several decades. The available research forms the basis for understanding how the medicine has been observed in different groups of patients. The evidence is generally focused on the research exploring pressure measurements inside the eye.

1. Evidence for Use in Elevated Intraocular Pressure (IOP)

The primary body of research on Proflax includes Randomized Controlled Trials (RCTs) and systematic reviews applied in research contexts involving fluctuating or unstable symptoms of elevated pressure in the eye. These studies were designed to examine measurements of Intraocular Pressure (IOP) in adults diagnosed with ocular hypertension or Chronic Open-Angle Glaucoma (OAG). Researchers focused on how IOP measurements changed from the start of the study over defined time intervals.

Studies consistently reported measurements of IOP change across the study duration in groups receiving Proflax compared to initial baseline measurements. In addition, comparative trials monitored IOP measurements against those recorded for other active treatment agents. The findings describe patterns observed in these studies, but research does not determine whether an individual will respond similarly.

2. Evidence for Use in Chronic Open-Angle Glaucoma (OAG)

Proflax was evaluated in long-term RCTs, observational cohort studies, and meta-analyses exploring its role in conditions characterized by fluctuating or episodic manifestations of elevated eye pressure. Research examined outcomes related to time to glaucoma progression, the rate of Visual Field deterioration, and the maintenance of a pre-defined target IOP range in adult populations requiring chronic maintenance therapy.

Findings describe patterns where long-term IOP measurements were tracked against the recorded rate of optic nerve changes in the observed populations. Studies monitored how symptoms evolved in the observed populations, and the research highlights changes measured during the study period. Data are still emerging regarding the large-scale tracking of functional quality-of-life outcomes linked to vision preservation over very long periods (decades).

Key Studies & References

  1. Timolol Ophthalmic Solution: FDA Drug Label (DailyMed)
  2. NICE Guideline NG81: Glaucoma: diagnosis and management (Clinical Evidence Base for Beta-blockers)

Frequently Asked Questions (FAQ)

Common questions about Proflax (FAQ)

Q: Is Proflax the same as [Competitor Drug]?

A: Proflax and [Competitor Drug] are two different medications. While they may be used for related conditions, they contain different active ingredients. A healthcare provider is the best source to determine which treatment is appropriate for an individual's specific needs.

Q: How quickly does Proflax start working?

A: The time it takes for Proflax to have a noticeable effect can vary significantly among individuals. Clinical information indicates that it may take several weeks of consistent use before the full therapeutic benefit is observed. It is important to continue treatment as directed by a healthcare professional.

Q: What should I do if I miss a dose?

A: If a dose of Proflax is missed, official product labeling generally advises taking the missed dose as soon as it is remembered, unless it is nearly time for the next scheduled dose. If that is the case, the missed dose should be skipped, and the regular dosing schedule should be resumed. It is important not to double the dose to catch up. For specific guidance, it is best to consult the patient information leaflet or a pharmacist.

Q: Can I stop taking Proflax once my symptoms improve?

A: Discontinuing Proflax should only be done under the direction of a healthcare provider. Stopping the medication abruptly may lead to the return of symptoms or withdrawal effects, depending on the drug. A healthcare professional can advise on the safest way to adjust or discontinue treatment, often involving a gradual tapering process.

How should Proflax be stored and disposed of?

How to Store and Dispose of Proflax?

Proflax (Timolol ophthalmic solution) must be stored and handled according to strict regulatory guidelines to maintain its sterile nature and efficacy.

Storage Requirement Official Regulatory Statement
Temperature & Protection Store at room temperature (below 25°C) and keep the bottle in its outer carton to protect from light. Do not freeze.
Container & Stability Keep the original container tightly closed. The multi-dose solution must be discarded 28 days after the first opening. Avoid touching the dropper tip to any surface.
Safety Keep the medicine out of the sight and reach of children.
Disposal Do not dispose of unused or expired medicine in household waste or wastewater. Consult a pharmacist for instructions on proper disposal according to local environmental requirements.

These conditions ensure the solution remains stable and free from contamination as defined by official labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagArgentina

Equivalent of Proflax found in:

A-Z Index: